Expanding the armamentarium for metabolic dysfunction-associated steatohepatitis

Source
Lancet gastroenterology & hepatology - ISSN 2468-1253-9:12 (2024) p. 1066-1067

An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)

Source
Nature Metabolism - ISSN 2522-5812-6:6 (2024) p. 1178-1196
Author(s)
    Michele Vacca, Ioannis Kamzolas, Lea Morch Harder, Fiona Oakley, Christian Trautwein, Maximilian Hatting, Trenton Ross, Barbara Bernardo, Anouk Oldenburger, Sara Toftegaard Hjuler, Iwona Ksiazek, Daniel Linden, Detlef Schuppan, Sergio Rodriguez-Cuenca, Maria Manuela Tonini, Tamara R. Castaneda, Aimo Kannt, Cecilia M. P. Rodrigues, Simon Cockell, Olivier Govaere, Ann K. Daly, Michael Allison, Kristian Honnens de Lichtenberg, Yong Ook Kim, Anna Lindblom, Stephanie Oldham, Anne-Christine Andreasson, Franklin Schlerman, Jonathon Marioneaux, Arun Sanyal, Marta B. Afonso, Ramy Younes, Yuichiro Amano, Scott L. Friedman, Shuang Wang, Dipankar Bhattacharya, Eric Simon, Valerie Paradis, Alastair Burt, Ioanna Maria Grypari, Susan Davies, Ann Driessen, Hiroaki Yashiro, Susanne Pors, Maja Worm Andersen, Sven Francque, Luisa Vonghia, An Verrijken, Eveline Dirinck, Clifford Brass

Metabolic dysfunction-associated fibrosis 5 (MAF-5) score predicts liver fibrosis risk and outcome in the general population with metabolic dysfunction

Source
Gastroenterology - ISSN 0016-5085-167:2 (2024) p. 1-20
Author(s)

Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease

MASLD/MASH and type 2 diabetes : two sides of the same coin? From single PPAR to pan-PPAR agonists

Source
Diabetes research and clinical practice - ISSN 0168-8227-212 (2024) p. 1-11
Author(s)